DHR at a glance
Danaher Corporation (DHR, SEC CIK 313616) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 21, 2026, an 8-K current report on August 3, 2026 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Danaher Corporation (DHR) reported revenue of $24.6 billion (up 2.9% from FY2024) and net income of $3.6 billion. Diluted EPS was $5.05.
- As of June 30, 2026, 65 institutional investment managers tracked by SignalX reported holding Danaher Corporation (DHR) shares worth $49.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Blair Rainer on August 21, 2026 of 39,193 shares at $218.73 per share.
- In the last 90 days, DHR insiders reported 0 open-market purchases ($0) and 3 open-market sales ($12.7M) on Form 4, a net sale of $12.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $24.6B
- +2.9% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$12.7M
- 13F holders
- 65 funds
- $49.0B · +2 vs prior quarter
- Latest 8-K
- Aug 3, 2026
- Item 5.02 · Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- IEEPA tariff authority struck down by U.S. Supreme Court Feb 2026; administration pursuing new tariffs under alternative authority: full impact still uncertain
- ~59% of 2025 sales from outside U.S.; China alone ~11% of sales, with government-mandated volume-based procurement programs actively suppressing prices
- Sole/limited-source suppliers for key components; supply interruptions cannot be quickly remedied due to regulatory qualification requirements
- $18.4B outstanding debt as of Dec 31, 2025; additional debt expected to finance pending Masimo Corporation acquisition
- FDA staffing reductions risk delays to 510(k) clearances and inspection schedules across Danaher's regulated medical device product lines
Business Overview
- Global science/technology platform across Biotechnology, Life Sciences, and Diagnostics segments; high recurring-revenue model via consumables and direct sales in ~50 countries
- ~60,000 employees (associates) as of Dec 31, 2025; ~22,000 in North America, ~20,000 Western Europe, ~15,000 high-growth markets
- US geographic concentration notable: North America represents 41% of sales in the United States alone; high-growth markets (Eastern Europe, Middle East, Africa, Latin America, Asia ex-Japan/AU/NZ) flagged as key future growth driver
- EU MDR/IVDR compliance deadlines extended to May 2026–Dec 2028 (MDR) and May 2026–May 2028 (IVDR), creating ongoing regulatory adaptation burden across Diagnostics and Life Sciences portfolios
- Life Sciences segment anchors on 2023 Abcam acquisition (protein consumables/antibodies), the most recent portfolio addition, reinforcing proteomics and drug-discovery consumables as strategic build-out priority
Management Discussion & Analysis
- Revenue $24.6B, up 3.0% YoY; core sales +2.0% driven by Biotechnology (+6.5% core) and Diagnostics (+1.5% core), offset by Life Sciences (-1.5% core)
- Operating margin 19.1% vs 20.4%; gross margin 59.1% vs 59.5%; SG&A 33.5% vs 32.5% of sales, pressured by $533M impairment charges
- Best segment: Biotechnology, sales $7.3B (+8.0%), operating margin 25.6% vs 24.9%; worst: Life Sciences, flat sales $7.3B, operating margin collapsed to 7.1% vs 12.0%
- Operating cash flow $6.4B; capex $1.2B; share buybacks $3.1B; dividends $878M; net debt rose to ~$18.4B total debt vs $16.0B in 2024
- 2026 outlook: Bioprocessing growth trend similar to 2025; Life Sciences modest improvement but below historical levels; Diagnostics higher growth as China headwinds ease; tariff costs <$300M in 2025 with ongoing uncertainty from trade policy shifts
AI summary of the DHR 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 26, 2026
Management Discussion & Analysis
- Q2 revenue up 5.5% YoY; core sales up 3.0%, or 4.5% excluding respiratory testing
- Operating margin 18.0% vs 12.8% YoY, up 520 basis points
- Life Sciences strongest core-sales contributor; Diagnostics benefited from Masimo acquisition
- Masimo acquired for approximately $9.8B, financed with cash and new debt
- Outlook headwinds: tariff uncertainty, Middle East logistics costs, currency exposure and potential demand pressures
Risk Factors
- New risk: Middle East military conflict during 2026, disrupting energy supplies and supply chains
- Regulatory risk: Sanctions and embargoes from military conflicts threatening business operations
- Market risk: Capital-markets volatility and increased cyber-attacks from escalating hostilities
- Cost risk: Higher energy and supply costs creating inflationary pressures
- Financial risk: Capital-markets dislocation potentially adversely affecting financial statements
AI summary of the DHR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- August 3, 2026 press release announced a leadership transition
- Leadership changes may affect strategic execution and management continuity
Item 7.01: Regulation FD Disclosure
- Reg FD disclosure includes standard non-filing language for the furnished information
- Information excluded from Exchange Act Section 18 liability
Item 8.01: Other Events
- Forward-looking disclosure highlights anticipated growth, Long-Term Growth Program benefits, and pending StatLab acquisition
- StatLab transaction remains subject to customary closing conditions, including regulatory clearances
Item EX-99.1: Item EX-99.1
- Julie Sawyer Montgomery becomes CEO and board member October 1, 2026, marking a planned leadership succession
- Rainer Blair retires October 1 after six years as CEO, remaining senior advisor through March 31, 2027
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 contains only a disclosure-status provision, not operating results or financial metrics
- The section is furnished rather than filed under Exchange Act Section 18, limiting liability and incorporation into other filings
Item EX-99.1: Item EX-99.1
- Q2 revenue $6.3B, up 5.5%; GAAP net earnings $870M, up 60%, signaling strong operating leverage
- Adjusted EPS $1.94, up 8%; operating cash flow $1.5B and free cash flow $1.3B strengthened funding capacity
Item 8.01: Other Events
- CHF 2.38B senior notes issued across maturities from 2031 to 2056
- Fixed coupons range from 1.65% to 2.51%, limiting exposure to future rate increases
AI summaries of DHR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DHR
Don't miss the next DHR filing
- Alerts as it files. A push when DHR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DHR, by share count.
- Ask anything. An AI agent that reads every DHR filing and answers with sources.
DHR alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Blair Rainer | Sell | Aug 21, 2026 | 39,193 | $218.73 |
| Blair Rainer | Sell | Aug 21, 2026 | 7,755 | $219.35 |
| Blair Rainer | Sell | Aug 21, 2026 | 11,307 | $217.77 |
| Gutierrez-Ramos Jose-Carlos | A | Aug 4, 2026 | 13,477 | - |
| Bouda Christopher | A | Aug 4, 2026 | 12,286 | - |
| Riley Christopher Paul | A | Aug 4, 2026 | 41,072 | - |
| Sawyer Montgomery Julie A | A | Aug 4, 2026 | 245,701 | - |
| Gugino Matthew E | A | Aug 4, 2026 | 153,563 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $23.9B | $24.6B |
| Gross Profit | - | $14.2B | $14.5B |
| Operating Income | - | $4.9B | $4.7B |
| Net Income | - | $3.9B | $3.6B |
| Gross Margin | - | 59.5% | 59.1% |
| Op. Margin | - | 20.4% | 19.1% |
| Net Margin | - | 16.3% | 14.7% |
| Balance Sheet | |||
| Total Assets | $84.5B | $77.5B | $83.5B |
| Equity | - | $49.5B | $52.5B |
| ROE | - | 7.9% | 6.9% |
| Per Share | |||
| EPS | - | $5.29 | $5.05 |
| Cash Flow | |||
| Operating CF | - | $6.7B | $6.4B |
| CapEx | $1.4B | $1.4B | $1.2B |
Source: XBRL data in Danaher Corporation (DHR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DHR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 65 | $49.04B |
| Q1 2026 | 63 | $48.72B |
| Q4 2025 | 64 | $59.56B |
| Q3 2025 | 65 | $54.88B |
| Q2 2025 | 64 | $49.59B |
| Q1 2025 | 60 | $37.99B |
| Q4 2024 | 60 | $36.34B |
| Q3 2024 | 53 | $20.69B |
- FMR LLC (Fidelity)+7.01M (+31%)
- BlackRock+3.44M (+7%)
- Millennium Management+1.96M (+1071%)
- Goldman Sachs Group+755.6K (+16%)
- State Street Corp+561.8K (+2%)
- JPMorgan Chase & Co−4.73M (-28%)
- T. Rowe Price Group−3.90M (-25%)
- Two Sigma Investments−1.41M (-76%)
- Bank of America Corp−1.03M (-17%)
- D.E. Shaw & Co−1.02M (-71%)
- Tiger Global Management+456.0K
- Loews Corporation+75.0K
- First Bancorp, Inc /ME/+839
Source: 13F-HR filings on SEC EDGAR (aggregated from 494 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DHR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 21, 2026 | - | Analysis | - |
| 10-Q | Jul 21, 2026 | Jun 26, 2026 | Analysis | |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 16, 2026 | - | - | - |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 19, 2026 | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
DHR SEC filings: frequently asked questions
Are DHR insiders buying or selling?
In the last 90 days, Danaher Corporation (DHR) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $12.7 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DHR stock?
As of June 30, 2026, the largest Danaher Corporation (DHR) holders among the 13F filers tracked by SignalX were BlackRock ($10.5 billion), Vanguard Capital Management LLC ($7.9 billion), FMR LLC (Fidelity) ($5.6 billion), State Street Corp ($5.4 billion), Vanguard Portfolio Management LLC ($2.7 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DHR's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Danaher Corporation (DHR) reported revenue of $24.6 billion (up 2.9% from FY2024) and net income of $3.6 billion. Diluted EPS was $5.05. The figures come from the XBRL data in the 10-K.
What are the main risks in DHR's latest 10-K?
In the 10-K filed February 24, 2026, Danaher Corporation (DHR) flagged: IEEPA tariff authority struck down by U.S. Supreme Court Feb 2026; administration pursuing new tariffs under alternative authority: full impact still uncertain. ~59% of 2025 sales from outside U.S.; China alone ~11% of sales, with government-mandated volume-based procurement programs actively suppressing prices. (AI summary of the Risk Factors section.)
What did DHR report in its latest 8-K?
Danaher Corporation (DHR) filed an 8-K on August 3, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers), Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). August 3, 2026 press release announced a leadership transition.
What are the latest DHR SEC filings?
Danaher Corporation (DHR) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on July 21, 2026, an 8-K current report on August 3, 2026 and a Form 4 insider filing on August 24, 2026.
What is DHR's SEC CIK number?
Danaher Corporation (DHR)'s SEC Central Index Key (CIK) is 313616. EDGAR lists every DHR filing under that number.
Ask anything about DHR
The research agent reads DHR's filings, financials, insider trades and 13F holders, then answers with sources.